Eagle Pharmaceuticals (EGRX) Stock Rating Upgraded by BidaskClub

Eagle Pharmaceuticals (NASDAQ:EGRX) was upgraded by investment analysts at BidaskClub from a “hold” rating to a “buy” rating in a report released on Thursday.

A number of other equities analysts have also weighed in on the company. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $75.00 price objective (down previously from $81.00) on shares of Eagle Pharmaceuticals in a research note on Thursday, November 9th. ValuEngine lowered Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Sunday, December 31st. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $75.00 price objective on shares of Eagle Pharmaceuticals in a research note on Friday, October 27th. Zacks Investment Research lowered Eagle Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 9th. Finally, Mizuho reaffirmed a “sell” rating and issued a $37.00 price objective on shares of Eagle Pharmaceuticals in a research note on Wednesday, November 8th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $63.67.

Shares of Eagle Pharmaceuticals (NASDAQ EGRX) opened at $56.81 on Thursday. The company has a debt-to-equity ratio of 0.26, a current ratio of 5.30 and a quick ratio of 5.15. The company has a market capitalization of $836.66, a PE ratio of 8.84 and a beta of 1.25. Eagle Pharmaceuticals has a 1 year low of $45.05 and a 1 year high of $97.15.

Eagle Pharmaceuticals (NASDAQ:EGRX) last issued its quarterly earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported $1.07 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.50. Eagle Pharmaceuticals had a return on equity of 62.60% and a net margin of 36.95%. sell-side analysts expect that Eagle Pharmaceuticals will post 2.23 EPS for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Virtu Financial LLC bought a new position in shares of Eagle Pharmaceuticals in the fourth quarter worth about $314,000. Royce & Associates LP boosted its stake in shares of Eagle Pharmaceuticals by 34.5% in the fourth quarter. Royce & Associates LP now owns 91,334 shares of the specialty pharmaceutical company’s stock worth $4,879,000 after acquiring an additional 23,418 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of Eagle Pharmaceuticals by 15.3% in the fourth quarter. Bank of New York Mellon Corp now owns 154,885 shares of the specialty pharmaceutical company’s stock worth $8,275,000 after acquiring an additional 20,608 shares during the period. Rhumbline Advisers boosted its stake in Eagle Pharmaceuticals by 14.2% during the fourth quarter. Rhumbline Advisers now owns 19,501 shares of the specialty pharmaceutical company’s stock valued at $1,042,000 after buying an additional 2,425 shares during the last quarter. Finally, Arizona State Retirement System boosted its stake in Eagle Pharmaceuticals by 219.2% during the fourth quarter. Arizona State Retirement System now owns 14,044 shares of the specialty pharmaceutical company’s stock valued at $750,000 after buying an additional 9,644 shares during the last quarter.

ILLEGAL ACTIVITY WARNING: “Eagle Pharmaceuticals (EGRX) Stock Rating Upgraded by BidaskClub” was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://sportsperspectives.com/2018/02/10/eagle-pharmaceuticals-egrx-stock-rating-upgraded-by-bidaskclub.html.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply